Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.Read More
DUBLIN, Ireland and TREVOSE, Pa., May 25, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP), a global commercial-stage biopharmaceut....
~ Strongbridge Commercial Introduction of KEVEYIS® (dichlorphenamide) in Mid-April Shows Encouraging Initial Demand ~ ~ RECORLEV™ (levoketoconazole)....
© 2016 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA ™ is a trademark of Strongbridge Biopharma plc.
KEVEYIS ® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.
MLR010 V7 12/2016